|
1
|
Blanchard EM: Cisplatin and solid tumours:
still working, after all these years. J Solid Tumors. 2:26–33.
2012.
|
|
2
|
Chaudhary UB and Haldas JR: Long-term
complications of chemotherapy for germ cell tumours. Drugs.
63:1565–1577. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tewari KS and Monk BJ: Gynecologic
Oncology Group trials of chemotherapy for metastatic and recurrent
cervical cancer. Curr Oncol Rep. 7:419–434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Armstrong DK, Bookman MA, McGuire W,
Bristow RE, Schilder JM and Group GO: A phase I study of
paclitaxel, topotecan, cisplatin and filgrastim in patients with
newly diagnosed advanced ovarian epithelial malignancies: a
Gynecologic Oncology Group study. Gynecol Oncol. 105:667–671. 2007.
View Article : Google Scholar
|
|
5
|
Ridwelski K, Gebauer T, Fahlke J, et al:
Combination chemotherapy with docetaxel and cisplatin for locally
advanced and metastatic gastric cancer. Ann Oncol. 12:47–51. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee KW, Kim JH, Yun T, et al: Phase II
study of low-dose paclitaxel and cisplatin as a second-line therapy
after 5-fluorouracil/platinum chemotherapy in gastric cancer. J
Korean Med Sci. 22(Suppl): S115–S121. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cullen KJ, Yang Z, Schumaker L and Guo Z:
Mitochondria as a critical target of the chemotheraputic agent
cisplatin in head and neck cancer. J Bioenerg Biomembr. 39:43–50.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vokes EE: Induction chemotherapy for head
and neck cancer: recent data. Oncologist. 15(Suppl 3): 3–7. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Niell HB, Herndon JE, Miller AA, et al:
Randomized phase III intergroup trial of etoposide and cisplatin
with or without paclitaxel and granulocyte colony-stimulating
factor in patients with extensive-stage small-cell lung cancer:
Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 23:3752–3759.
2005. View Article : Google Scholar
|
|
10
|
Bosch ME, Sánchez AJ, Rojas FS and Ojeda
CB: Analytical methodologies for the determination of cisplatin. J
Pharm Biomed Anal. 47:451–459. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hohnloser JH, Schierl R, Hasford B and
Emmerich B: Cisplatin based chemotherapy in testicular cancer
patients: long term platinum excretion and clinical effects. Eur J
Med Res. 1:509–514. 1996.PubMed/NCBI
|
|
12
|
Gietema JA, Meinardi MT, Messerschmidt J,
et al: Circulating plasma platinum more than 10 years after
cisplatin treatment for testicular cancer. Lancet. 355:1075–1076.
2000.PubMed/NCBI
|
|
13
|
Brouwers EE, Huitema AD, Beijnen JH and
Schellens JH: Long-term platinum retention after treatment with
cisplatin and oxaliplatin. BMC Clin Pharmacol. 8:72008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tothill P, Klys HS, Matheson LM, McKay K
and Smyth JF: The long-term retention of platinum in human tissues
following the administration of cisplatin or carboplatin for cancer
chemotherapy. Eur J Cancer. 28A:1358–1361. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gerl A and Schierl R: Urinary excretion of
platinum in chemotherapy-treated long-term survivors of testicular
cancer. Acta Oncol. 39:519–522. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gregg RW, Molepo JM, Monpetit VJ, et al:
Cisplatin neurotoxicity: the relationship between dosage, time, and
platinum concentration in neurologic tissues, and morphologic
evidence of toxicity. J Clin Oncol. 10:795–803. 1992.PubMed/NCBI
|
|
17
|
DeConti RC, Toftness BR, Lange RC and
Creasey WA: Clinical and pharmacological studies with
cis-diamminedichloroplatinum (II). Cancer Res. 33:1310–1315.
1973.PubMed/NCBI
|
|
18
|
Go RS and Adjei AA: Review of the
comparative pharmacology and clinical activity of cisplatin and
carboplatin. J Clin Oncol. 17:409–422. 1999.PubMed/NCBI
|
|
19
|
Schweitzer VG: Cisplatin-induced
ototoxicity: the effect of pigmentation and inhibitory agents.
Laryngoscope. 103:1–52. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lautermann J, Song B, McLaren J and
Schacht J: Diet is a risk factor in cisplatin ototoxicity. Hear
Res. 88:47–53. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tanaka F, Whitworth CA and Rybak LP:
Influence of pH on the ototoxicity of cisplatin: a round window
application study. Hear Res. 177:21–31. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bertolaso L, Martini A, Bindini D, et al:
Apoptosis in the OC-k3 immortalized cell line treated with
different agents. Audiology. 40:327–335. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hyppolito MA, de Oliveira JA and Rossato
M: Cisplatin ototoxicity and otoprotection with sodium salicylate.
Eur Arch Otorhinolaryngol. 263:798–803. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Previati M, Lanzoni I, Corbacella E, et
al: RNA expression induced by cisplatin in an organ of
Corti-derived immortalized cell line. Hear Res. 196:8–18. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arafa HM, Abdel-Hamid MA, El-Khouly AA,
Elmazar MM and Osman AM: Enhancement by dexamethasone of the
therapeutic benefits of cisplatin via regulation of tumor
angiogenesis and cell cycle kinetics in a murine tumor paradigm.
Toxicology. 222:103–113. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Drottar M, Liberman MC, Ratan RR and
Roberson DW: The histone deacetylase inhibitor sodium butyrate
protects against cisplatin-induced hearing loss in guinea pigs.
Laryngoscope. 116:292–296. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hatzopoulos S, Di Stefano M, Albertin A
and Martini A: Evaluation of cisplatin ototoxicity in a rat animal
model. Ann NY Acad Sci. 884:211–225. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Previati M, Lanzoni I, Astolfi L, et al:
Cisplatin cytotoxicity in organ of Corti-derived immortalized
cells. J Cell Biochem. 101:1185–1197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Previati M, Lanzoni I, Corbacella E, et
al: Cisplatin-induced apoptosis in human promyelocytic leukemia
cells. Int J Mol Med. 18:511–516. 2006.PubMed/NCBI
|
|
31
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Timmer-Bosscha H, Mulder NH and de Vries
EG: Modulation of cis-diamminedichloroplatinum(II) resistance: a
review. Br J Cancer. 66:227–238. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gosland M, Lum B, Schimmelpfennig J, Baker
J and Doukas M: Insights into mechanisms of cisplatin resistance
and potential for its clinical reversal. Pharmacotherapy. 16:16–39.
1996.PubMed/NCBI
|
|
34
|
Adjei AA, Budihardjo II, Rowinsky EK, et
al: Cytotoxic synergy between pyrazoloacridine (NSC 366140) and
cisplatin in vitro: inhibition of platinum-DNA adduct removal. Clin
Cancer Res. 3:761–770. 1997.PubMed/NCBI
|
|
35
|
Rybak LP and Whitworth CA: Ototoxicity:
therapeutic opportunities. Drug Discov Today. 10:1313–1321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van den Berg JH, Beijnen JH, Balm AJ and
Schellens JH: Future opportunities in preventing cisplatin induced
ototoxicity. Cancer Treat Rev. 32:390–397. 2006.PubMed/NCBI
|
|
37
|
Daldal A, Odabasi O and Serbetcioglu B:
The protective effect of intratympanic dexamethasone on
cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck
Surg. 137:747–752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Astolfi L, Simoni E, Ciorba A and Martini
A: In vitro protective effects of Ginkgo biloba against cisplatin
toxicity in mouse cell line OCk3. Audiol Med. 6:251–258. 2008.
View Article : Google Scholar
|
|
39
|
Chen WC, Jackson A, Budnick AS, et al:
Sensorineural hearing loss in combined modality treatment of
nasopharyngeal carcinoma. Cancer. 106:820–829. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rademaker-Lakhai JM, Crul M, Pluim D, et
al: Phase I clinical and pharmacologic study of a 2-weekly
administration of cisplatin and gemcitabine in patients with
advanced non-small cell lung cancer. Anticancer Drugs.
16:1029–1036. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rivera F, Vega-Villegas ME, López-Brea MF,
et al: Long term results of a phase II trial of induction
chemotherapy with uracil-ftegafur (UFT), vinorelbine and cisplatin
(UFTVP) followed by radiotherapy concomitant with UFT and
carboplatin (RT/UFTJ) in non-resectable locally advanced (stage
IV-B) squamous cell head and neck carcinoma and peripheral blood
stem cell support (PBSCS) with febrile neutropenia. Clin Transl
Oncol. 9:40–47. 2007.
|
|
42
|
Uhm JE, Lim HY, Kim WS, et al: Paclitaxel
with cisplatin as salvage treatment for patients with previously
treated advanced transitional cell carcinoma of the urothelial
tract. Neoplasia. 9:18–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zuur CL, Simis YJ, Verkaik RS, et al:
Hearing loss due to concurrent daily low-dose cisplatin
chemoradiation for locally advanced head and neck cancer. Radiother
Oncol. 89:38–43. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Regione Emilia-Romagna certified
(Internet). Reportistica predefinita REM anno. 2006, (updated 2007
Oct 30). Available from: http://www.regione.emilia-romagna.it/sas/rem/report_predef/2006/REM05_2.htm.
|
|
45
|
Kris MG, Hesketh PJ, Somerfield MR, et al:
American Society of Clinical Oncology guideline for antiemetics in
oncology: update 2006. J Clin Oncol. 24:2932–2947. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Atallah E and Flaherty L: Treatment of
metastatic malignant melanoma. Curr Treat Options Oncol. 6:185–193.
2005. View Article : Google Scholar
|
|
47
|
von der Maase H: Current and future
perspectives in advanced bladder cancer: is there a new standard?
Semin Oncol. 29:3–14. 2002.PubMed/NCBI
|
|
48
|
Tiseo M and Ardizzoni A: Chemotherapy in
the treatment of thymic tumours. Oncol Rev. 2:95–101. 2008.
View Article : Google Scholar
|
|
49
|
Girard N, Mornex F, Van Houtte P, Cordier
JF and van Schil P: Thymoma: a focus on current therapeutic
management. J Thorac Oncol. 4:119–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
National Cancer Institute.
Gastrointestinal Complications PDQ®. 2012, National
Cancer Institute; Bethesda, MD: (Updated 07/18/2012). Available
from: http://cancer.gov/cancertopics/pdq/supportivecare/gastrointestinalcomplications/HealthProfessional.
|
